Sign In
Buy PPCB
$1.02
-0.0300 (-2.86%)
At Close: Aug 04, 2026
The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
08:45am, Tuesday, 03'rd Mar 2026
MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
08:45am, Wednesday, 18'th Feb 2026
We are pleased with advancements made with our R&D programs and
As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
08:45am, Tuesday, 20'th Jan 2026
MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chron
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
08:45am, Thursday, 15'th Jan 2026
This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma's pancreatic proenzyme formulation known as PRP.
Propanc Biopharma Provides Shareholder Update
08:45am, Tuesday, 13'th Jan 2026
MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
07:00am, Monday, 22'nd Dec 2025
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
08:45am, Thursday, 04'th Dec 2025
MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
08:45am, Monday, 01'st Dec 2025
These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis
Propanc Biopharma (OTCMKTS:PPCB) Shares Down 3.7% – Should You Sell?
02:16am, Friday, 21'st Nov 2025
Shares of Propanc Biopharma Inc (OTCMKTS:PPCB - Get Free Report) dropped 3.7% on Thursday. The company traded as low as $0.7898 and last traded at $0.8277. Approximately 46,204 shares were traded duri
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
08:45am, Monday, 17'th Nov 2025
MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurre
MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients
We aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.
